| Reason for discontinuation . | No. of patients [%] . |
|---|---|
| Worsening of perianal disease | 3 [1.7%] |
| Skin rash | 3 [1.7%] |
| Lost to follow-up | 4 [2.2%] |
| antidrug antibodies | 2 [2.2%] |
| Neuropathy | 1 [0.6%] |
| Worsening of disease activity | 1 [0.6%] |
| Reason for discontinuation . | No. of patients [%] . |
|---|---|
| Worsening of perianal disease | 3 [1.7%] |
| Skin rash | 3 [1.7%] |
| Lost to follow-up | 4 [2.2%] |
| antidrug antibodies | 2 [2.2%] |
| Neuropathy | 1 [0.6%] |
| Worsening of disease activity | 1 [0.6%] |
SC, subcutaneous.
| Reason for discontinuation . | No. of patients [%] . |
|---|---|
| Worsening of perianal disease | 3 [1.7%] |
| Skin rash | 3 [1.7%] |
| Lost to follow-up | 4 [2.2%] |
| antidrug antibodies | 2 [2.2%] |
| Neuropathy | 1 [0.6%] |
| Worsening of disease activity | 1 [0.6%] |
| Reason for discontinuation . | No. of patients [%] . |
|---|---|
| Worsening of perianal disease | 3 [1.7%] |
| Skin rash | 3 [1.7%] |
| Lost to follow-up | 4 [2.2%] |
| antidrug antibodies | 2 [2.2%] |
| Neuropathy | 1 [0.6%] |
| Worsening of disease activity | 1 [0.6%] |
SC, subcutaneous.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
